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Abstract: Alzheimer’s disease (AD) is the most common cause of dementia, affecting the central
nervous system (CNS) through the accumulation of intraneuronal neurofibrillary tau tangles (NFTs)
and β-amyloid plaques. By the time AD is clinically diagnosed, neuronal loss has already occurred in
many brain and retinal regions. Therefore, the availability of early and reliable diagnosis markers
of the disease would allow its detection and taking preventive measures to avoid neuronal loss.
Current diagnostic tools in the brain, such as magnetic resonance imaging (MRI), positron emission
tomography (PET) imaging, and cerebrospinal fluid (CSF) biomarkers (Aβ and tau) detection are
invasive and expensive. Brain-secreted extracellular vesicles (BEVs) isolated from peripheral blood
have emerged as novel strategies in the study of AD, with enormous potential as a diagnostic
evaluation of therapeutics and treatment tools. In addition; similar mechanisms of neurodegeneration
have been demonstrated in the brain and the eyes of AD patients. Since the eyes are more accessible
than the brain, several eye tests that detect cellular and vascular changes in the retina have also been
proposed as potential screening biomarkers. The aim of this study is to summarize and discuss
several potential markers in the brain, eye, blood, and other accessible biofluids like saliva and urine,
and correlate them with earlier diagnosis and prognosis to identify individuals with mild symptoms
prior to dementia.
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1. Introduction
1.1. Pathophysiology of AD and Clinical Manifestations
The lesions of Alzheimer’s disease (AD) include pathological changes in the brain such as the
accumulation of proteins (amyloid-β (Aβ) peptide and Tau); the degeneration of neurons and synapses,
most noticeably in the neocortex and the hippocampus, which leads to structural changes as well as to
the loss of functional connectivity, and the alterations of reactive processes like neuroinflammation and
plasticity, related to oxidative stress and mitochondrial dysfunction [1]. Some of these hallmarks can
be detected in the prodromal stage of the disease, also referred to as mild cognitive impairment (MCI)
due to AD, when the symptoms are not yet obvious.
Amyloid-β deposits are widely distributed in the brain and follow an anterograde sequence
originating in five phases in which different brain regions are hierarchically involved [2–4]. The five phases
go from phase 1, when the deposits are exclusively found in the isocortex, to phase 5, when the
cerebellum and several brainstem nuclei, such as the pontine nuclei and the locus coeruleus, among others,
are involved [2,4]. The progression of Tau pathology is also staggered from the transentorhinal and
entorhinal cortex to the isocortex via the hippocampus, with a heterogeneous and area-specific neuronal
loss [2–4]. It is well-established that the accumulation of Tau protein takes place specifically in neurons
and occurs in their cell body as neurofibrillary tangles (NFTs), in their dendrites as neuropil threads (NT),
and in their axons forming the senile plaque neuritic corona [3].
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The Braak stages, based on phospho-Tau accumulation within connected brain regions, defines the
progression of AD neuropathology. I–II refer to the entorhinal cortex, III–IV to the hippocampus/limbic
system, and V–VI to the frontal and parietal lobes.
1.2. Diagnostic Tools
The progress in the diagnosis of AD has noticeably improved with the development in the last decades
of noninvasive neuroimaging techniques that allow the visualization of structures in vivo. Some examples
are novel magnetic resonance imaging (MRI), metabolic changes detected by positron emission tomography
(PET), and amyloid imaging. These techniques permit the detection of pre-symptomatic diagnostic
biomarkers in the brains of cognitively normal elderly individuals and also serve to monitor disease
progression after the onset of symptoms [1]. Due to their reliability and high discriminative capacity in the
pre-dementia state, volumetric approaches of the high-resolution subfield are useful, as well as diagnostic
techniques in order to study the early changes in the most affected brain structures [2–4]. With all these
tools, the typical lesions related to protein accumulation and the structural changes in certain brain areas
are easier to detect and; therefore, constitute the basis of the diagnosis.
In addition, the advancement in the past few years of omics technologies (genomics, transcriptomics,
proteomics, metabolomics, secretomics, etc.) has made possible the analysis of a wide range of AD
hallmarks referring to both, sporadic and familial cases. These tools facilitate the analysis of human
fluid samples of diverse nature such as blood, tears, urine, or saliva, whose collection in most cases does
not require trained professionals and has the advantage of being noninvasive due to easy accessibility.
The importance of identifying and developing reliable and sensitive tools for the early diagnosis of AD
relies on the potential benefits for the patients, including timely access to medical treatments to slow
down the progression of the disease and; therefore, preservation of longer cognitive capacity, or even the
possibility to plan for the future.
2. Invasive Biomarkers
2.1. Changes in Specific Brain Areas as Early Biomarkers
The locus coeruleus (LC) is a neuromelanin-rich brainstem structure thought to modulate attention
and memory and is the major source of noradrenaline in the brain. In the asymptomatic stage of
AD, Tau NFTs are observed in the LC [5,6] prior to their presence in other cerebral areas such as the
entorhinal cortex and the neocortex [7–10]. These Tau aggregates precede typical neuronal loss in
the LC during AD progression [11]. Studies using unbiased stereology have revealed an average
decrease in LC volume of 8.4% for each Braak stage increment, as well as neuronal loss mainly in the
rostral/middle area of the LC, progressing from 30% in the prodromal stage to 55% when dementia is
diagnosed [11]. Functionally, this neuronal loss has correlated with cognitive dysfunction [12] and
reduced noradrenaline levels in the hippocampus and the cortex [13]. Additionally, a two-fold increase
in Tau accumulation was also observed from Braak stage 0 to I [9]. Therefore, the detection using
in vivo imaging of early structural tissue modifications such as the decrease in the LC volume or
metabolic changes would support the diagnosis and could potentially slow down disease progression
if the patient benefits from treatments in the appropriate time [14,15].
Although there is controversy regarding the accelerated rates of brain atrophy at the preclinical
stage of the disease, it seems that the medial temporal lobe and, particularly, the hippocampus are
brain structures early affected by NFTs and neurite loss. Studies using voxel-based morphometry and
high-resolution MRI have revealed hippocampal atrophy in AD patients’ brains at the preclinical stage,
up to 10 years before the diagnosis of dementia [16], and even before MCI [17,18]. The magnitude of
atrophy in the hippocampus and its subfields determines the progression to either MCI or AD [19–21].
Thus, studies using radial atrophy measurements have shown that CA1 and the subicular atrophy
in cognitively healthy individuals is associated with an increased risk of developing MCI, while the
gradual involvement of the CA1 and subiculum fields, along with atrophy spread to the rest of
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the hippocampus (CA2–3 subfields) in amnestic MCI, suggests the future diagnosis of AD [22,23].
Moreover, apolipoprotein E (ApoE) plays a significant role in AD pathogenesis by affecting amyloid
and Tau pathology. The presence of the allele ε4 (APOEε4) [24] influences the reduction of the
hippocampal volume and the accumulation of Aβ filaments in the brains of elderly people without
cognitive impairment and normal levels of Aβ-peptides morphologically [25–27]. In this direction,
MRI imaging has revealed a significant reduction in the hippocampal volume in amnestic MCI people
carrying APOEε4, especially in those who progressed to AD [28]. Even cognitively normal APOEε4
carriers have shown hippocampal volume and cortical thickness reduction together with memory
decline and accelerated brain atrophy rates before the onset of cognitive impairment [24,27].
Regarding neuronal connectivity dysfunction, a novel PET tracer that binds to synaptic vesicle
glycoprotein 2A (SV2A) can be used to quantify synaptic density in vivo, predicting the stage of AD [29].
Several morphological studies have shown that synaptic loss appears early in the pathology [30,31], so the
study of markers of neuronal death may derive in promising results for the early diagnosis of AD.
In conclusion, in vivo morphological studies of different brain areas (LC, hippocampus, etc.),
along with genetic studies that detect alleles or mutations closely related to the pathology, point out
their usefulness as biomarkers for the early detection of AD. Despite the high prognostic ability of
these techniques in AD and MCI [32], sometimes, there are limitations that make it difficult to use
them in the routine analysis [33]. For this reason, biomarkers in cerebrospinal fluid (CSF) are being
extensively studied worldwide as potential candidates for the diagnosis of AD before the appearance
of cognitive symptoms [34].
2.2. Cerebrospinal Fluid
There is no doubt the ideal fluid biomarker should have a series of characteristics—reliable,
reproducible, and noninvasive in terms of collection, specific for a particular disease,
simple, and inexpensive to measure, and easy to implement in large populations. In this regard,
blood biomarkers meet several of these criteria and could be used in primary care to identify
patients with risk of AD [35]. In contrast, CSF collection does not meet the criteria of being a
noninvasive procedure, which certainly limits its use but given the close relationship between the
brain and the CSF, this fluid could provide valuable information about the biochemical changes
that occur in the brain at the preclinical stages of AD [36]. For instance, it is well established that
decreased Aβ-42 and elevated total Tau and phospho-Tau in CSF are considered specific markers of
AD [37,38], and that these biomarkers can predict cognitive decline over time [39]. The advantages
and disadvantages of each category of fluid biomarkers (blood, CSF, and other matrices such as
tears, saliva, and urine) are summarized in Table 1.
Table 1. Advantages and disadvantages for each category of biological fluids used to isolate Alzheimer’s
disease biomarkers.
Advantages Disadvantages
CSF
Close relationship with the brain
High accuracy in the diagnostic process
Ability to test a large number of candidate
pathophysiological biomarkers
High concentration of the biomarkers
Invasive
Clinicians require training
Positioned in later disease stages,
after blood samples, as a confirmatory
diagnostic modality
Process less accepted by the population
and at the risk of causing harm, anxiety,
and fear to the patient
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Table 1. Cont.
Advantages Disadvantages
Blood
Noninvasive, fast and convenient
Inexpensive and reproducible
Simple to measure (well-established as part of
clinical routines globally)
No prior training of the clinicians is required
Can be performed in a large variety of settings
(primary care, hospitals, patient’s home . . . )
Easy to implement in large populations
Ability to test a large number of candidate
pathophysiological biomarkers
First-step of the multi-stage diagnostic
process (identification of patients at the
earliest stages of the disease)
Less accurate
Presence of very low concentrations of the
biomarkers once they have crossed the
blood-brain barrier and decreased time
window for testing
Less consistent results (susceptibility to
interference with other components)
Other matrices
(tears, saliva,
and urine)
Extremely noninvasive
Repeatable collections
Easy, no risk of infection, can be
self-collected by the patient
Cheap
Stress-free
Remarkable lack of validated studies
Lack of results replicated in larger,
multicenter and longitudinal studies
Nowadays, novel molecular markers are being evaluated in CSF through omics technologies,
which allow measuring a large number of analytes at a time (Figure 1). For example, a mass
spectroscopy-based analysis revealed that similar levels of ApoE and its isoforms (ApoE2, ApoE3,
and ApoE4) were found in the CSF of AD patients and non-AD individuals, independent of their
APOE genotype (APOEε2, APOEε3, or APOEε4). However, CSF total ApoE concentrations were
positively associated with CSF total Tau and phospho-Tau levels [40,41].
J. Pers. Med. 2020, 10, x FOR PEER REVIEW 4 of 26 
 
Blood 
Noninvasive, fast and convenient 
Inexpensive and reproducible 
Simple to measure (well-established 
as part of clinical routines globally) 
 prior training of the clinicians is 
required 
Can be performed in a large variety 
of settings (primary care, hospitals, 
patient’s home…) 
Easy to implement in large 
populations 
Ability to test a large number of 
candidate pathophysiological 
biomarkers 
First-step of the multi-stage 
diagnostic process (identification of 
patients at the earliest stages of the 
disease) 
Less accurate 
Presence of very low concentrations of 
the biomarkers once they have crossed 
the blood-brain barrier and decreased 
time window for testing 
Less consistent results (susceptibility to 
interf rence with oth r components) 
Other 
matrices 
(tears, saliva, 
and urine) 
Extremely noninvasive 
Repeatable collections 
Easy, no risk of infection, can be self-
collected by the patient  
Cheap 
Stress-free 
Remarkable lack of validated studies 
Lack of results replicated in larger, 
multicenter and longitudinal studies 
Nowadays, novel molecular arkers are being ev lu ted in CSF th ough omics technologies, 
which allow measuring a large number of analytes at a time (Figure 1). F r example, a mass 
spectroscopy-based analysis revealed that similar levels of ApoE and its isoforms (ApoE2, ApoE3, 
and ApoE4) were found in the CSF of AD patients and non-AD individuals, independent of their 
APOE genotype (APOEε2, APOEε3, or APOEε4). However, CSF total ApoE concentrations were 
positively associated with CSF total Tau and phospho-Tau levels [40,41]. 
 
Figure 1. Schematic overview of invasive biomarkers. Different biomarkers have been used to detect 
early anatomical changes in the brains of people with mild cognitive impairment, including the 
Figure 1. Schematic overvi w of invasive biomark . ifferent biomarkers hav been used to detect
early an tomic l changes i the brains of pe ple with mild cognitive impairment, including the atrophy
of specific brain areas like the locus coeruleus or the hippocampus, and the presence of typical protein
aggregates such as extracellular amyloid plaques or intracellular Tau-containing neurofibrillary tangles
(upper panel). Additionally, biomarkers of Alzheimer’s disease (AD)-related degenerative processes
like synaptic dysfunction, neuroinflammation, oxidative stress, or neuronal loss can be measured in the
cerebrospinal fluid of AD patients. The detection of miRNAs represents a novel and promising tool for
the early AD diagnosis (lower panel).
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Proteins involved in the pathological processing of the amyloid precursor protein (APP) could
be biomarker candidates for early AD diagnosis and must be considered. Presenilin 1 (PSEN1) and
β-secretase 1 (BACE1) are both enzymes involved in the cleavage of APP. In MCI patients, both PSEN1
and BACE1 levels and their activity were increased in CSF [42,43]. Moreover, elevated BACE1
expression has been associated with the APOEε4 genotype [43]. It is worth noting that BACE1 activity
was only increased in MCI patients whose impairment was progressing to more advanced stages of
dementia, and not occurring in stable MCI patients [44]. So, while BACE1 seems to be highlighted as a
sensitive early biomarker to detect alterations in the amyloidogenic process in APOEε4 carriers [43],
it does not seem to be a good candidate in APOEε4 non-carriers.
Other early aspects to highlight in AD are neuroinflammation and the synaptic dysfunction;
thus, specific markers of these processes could also play a very important role and may correlate
more directly with cognitive decline [45]. In this sense, many proteins involved in vesicular transport
(secretogranin II (SCG2), chromogranin A (CHGA)), in synapses formation and stabilization (neurexins
(NRXNs), neuronal pentraxin 1 (NPTX1), neurocan core protein (NCANP)), and in the immune
system (lysozime C (LysC) and β2-microglobulin (β2M)) were significantly higher in the CSF of
patients with MCI, especially in patients with MCI progressing to AD pathology than in AD and
healthy control patients [46]. According to one study, higher levels of CHGA in the CSF of healthy
elderly people predicted future decreases in Aβ-42 [47]. Other proteins that play a crucial role
in inflammation are YKL-40 and visinin-like protein-1 (VILIP-1). Increased expression of these
molecules has been seen in both MCI and AD patients, contrary to cognitively normal elderly subjects.
While YKL-40 was increased from the prodromal stage until the severe stage of the disease, VILIP-1 was
only increased in the prodromal stage [48]. Some studies have found an association between the
upregulation of YKL-40 with an increased risk of progression from the normal conditions to MCI [49].
Another potential inflammatory marker is the interferon-γ-induced protein 10 (IP-10), whose level was
increased in the CSF of asymptomatic elderly adults that also presented elevated levels of total-Tau and
phospho-Tau [50]. Likewise, monocyte chemoattractant protein 1 (MCP-1), a low-molecular-weight
cytokine involved in the inflammatory process, was found elevated in the CSF of MCI and AD
patients [51]. The triggering receptor expressed on myeloid cells 2 (TREM2), expressed by microglial
cells, among others, plays an important role in regulating immune responses in the brain and in the
production of inflammatory cytokines [52]. Its haplodeficiency has been associated with increased
axonal dystrophy and phospho-Tau accumulation around Aβ-plaques [53]. An increased level of CSF
soluble TREM2 has been seen in carriers of an autosomal dominant AD mutation, at least five years
before the onset of symptoms, although later to brain amyloidosis and Tau pathology [54]. All these
findings reveal that a large number of proteins involved in the inflammatory response can be potential
early biomarkers of AD.
One protein that plays an important role in memory enhancement is neurogranin. It is involved
in post-synaptic signaling pathways, and its CSF levels differentiated patients with early symptomatic
AD from controls with a comparable diagnostic utility to the other CSF biomarkers [55]. The potential
of neurogranin as a biomarker of AD depended on the fragment measured [56].
Regarding neuronal damage, some proteins such as neurofilament light chain (NF-L), a protein
involved in protecting neurites, and neuron-specific enolase (NSE), which plays a role in neuronal
metabolism, have revealed increased CSF concentrations in MCI patients in comparison with cognitively
elderly, and with patients at advanced AD stages [57,58]. In AD patients with advanced pathology,
high CSF NF-L levels are associated with cognitive decline and morphological changes in the brain
that indicate neuronal loss [57]. Schmidt et al. showed a correlation between high CSF NSE levels and
Tau pathology [58]. These results agree with studies, where plasma protein levels were also studied
and support the use of NF-L and NSE as early AD biomarkers [56].
Lipid alterations in CSF participate as well in the modulation of neuropathological events related
to AD and can be an AD biomarker candidate. In patients with incipient dementia, a reduction of up to
40% of sulfatide levels was observed [59] The levels of some other lipids such as phosphocholine and
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sphingomyelin were increased in patients at the prodromal stage and correlated with amyloid and Tau
pathology [60]. Another biomarker candidate is the fatty acid-binding protein (FABP3), which may
play a role in neuronal synapse formation. In MCI and AD patients, the FABP3 level was higher than
in cognitively healthy people [61], and it was related to early structural brain changes typical of AD
patients (entorhinal cortex atrophy). Also, high FABP3 levels have been found in non-amnestic elderly
APOEε4 carriers [62], showing their increase occurs at a very early stage of the disease [63].
Overall, all the findings mentioned above reflect changes in specific areas of the brain detected
using novel imaging techniques (MRI, PET), the presence of two classical AD proteins (Aβ and Tau),
and the progression of processes such as neuronal apoptosis, synaptic loss, and inflammation. Many of
them are still under consideration as potential early biomarkers of AD, and larger longitudinal studies
are required for validation of the results [56]. Unfortunately, most AD patients are asymptomatic
during the preclinical stages, complicating the recruitment for these kinds of studies and emphasizing
the importance of rapid diagnosis.
It is also relevant to investigate the presence of microRNAs (miRNAs), a big family of endogenous
short non-coding RNAs that regulate the number of mature mRNAs at the post-transcriptional level [64].
About 70% of identified miRNAs are expressed in the brain, and some miRNAs species are present in
exosomes, both good biomarker candidates in clinical diagnostics. Of the approximately 2000 human
miRNAs identified to date, no more than 40 are abundantly expressed in the brain [65]. The core CSF
biomarkers (Aβ-42, total-tau, and phospho-tau) are relatively stable in clinical AD, and although they
are useful for diagnosis, they are not good enough as indicators of disease progression. Although CSF
miRNAs are obtained in an invasive manner, which is far from ideal, they have the advantage of
targeting important pathological AD genes. A single miRNA has the potential to interfere with
the expression of a small family of genes. This is the case with miRNA-125b (upregulated in AD),
which targets the synaptic protein synapsin-2 (SYN-2), the enzyme 15-lipoxygenase (15-LOX), and the
cell cycle regulator CDKN2A. This opens up the door for the use of miRNAs as therapeutic agents in the
future. Furthermore, the misregulation of specific miRNAs could contribute to AD etiopathogenesis [66]
and partially explain the large number of brain mRNAs gradually and significantly downregulated in
anatomical regions sensitive to AD progression (reviewed in Lukiv 2013)[65]. Other attractive points
that favor the use of CSF miRNAs as diagnosis tools are their high stability in body fluids [67,68],
the low concentration required for their detection by standard molecular biology techniques, such as
quantitative RT-PCR, and the proven high predictive accuracy in the pathogenic process of AD. All of
the above supports the huge potential miRNAs offer as diagnostic and prognostic biomarkers and,
at the same time, as plausible therapeutic tools against AD [69].
In the hippocampus of AD patients, in comparison with healthy volunteers, upregulation
of three out of the 13 brain-associated miRNAs studied was observed: miRNA-9, miRNA125b,
and miRNA128 [66]. Very similar results were found in the CSF of AD patients. Using microarrays,
qRT-PCR and novel highly sensitive LNA, EDC and DIG (LED)-Northern dot-blot (an improved
northern blot-based protocol for small RNA detection that combines the use of digoxigenin (DIG)-labeled
oligonucleotide probes containing locked nucleic acids (LNA) and 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) for cross-linking the RNA to the membrane), high amounts of proinflammatory
miRNAs such as miRNA146a, miRNA-155, miRNA-9, and miRNA-125b have been detected in AD
patients CSF compared with age-matched controls [65,70,71]. Briefly, miRNA-125b targets synaptic
proteins, neurotrophic factors and cell regulator proteins, and miRNA146a targets immune system
regulators and proteins involved in proinflammatory signaling, as well as in Aβ accumulation [65].
Both miRNA-125b and miRNA-146a can explain many of the pathogenic effects of AD, so they could
be excellent candidates as AD biomarkers. In areas such as the frontal gyrus and the neocortex, the up-
and downregulation of an elevated number of miRNAs has been seen, and even some of them showed
different regulations according to the area studied [72]. miRNA-29a seems a promising biomarker
because it targets BACE1, which promotes the formation of Aβ from APP. In the cortex of AD patients,
decreased miRNA29a has been reported, while a two-fold increase in miR-29a levels was found in the
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CSF of AD patients in comparison with cognitively healthy people [73,74]. The decrease in miR-29
brain expression in AD patients can be associated with an increase of BACE1, leading to the subsequent
increase in Aβ levels [75]. Another miRNA that is upregulated in the neocortex, hippocampus, and CSF
is miRNA-9 [65,70]. MiRNA-9 is mainly involved in neurogenesis and brain cell proliferation [76,77]
and also targets BACE1, decreasing its expression [78]. In this sense, miRNA-29a and miRNA-9 could
be indicators of pathology acting as biomarkers. We have only named a few microRNAs involved in
AD, although it is worth noting that there are many more with promising results [79].
3. Noninvasive Biomarkers
3.1. Blood Biomarkers
Blood pressure has been pointed out as an early marker of AD. High blood pressure has been
associated with senile plaques, neurofilament tangles, and hippocampal atrophy, and advanced age
and hypertension have been linked to AD development [80]. In addition, selected low amounts of
brain proteins/substances can cross the blood-brain barrier, reaching the bloodstream. Therefore, it is
possible the detection in the blood of specific substances derived exclusively from the brain or systemic
pathologies [81]. Despite blood is a more complex matrix for investigating neuronal processes,
making the research of neurodegenerative biomarkers in blood challenging; its accessibility makes the
study and validation interesting. To this effect, blood represents a noninvasive way of monitoring AD
development and progression [82].
Compared with CSF, blood is easily collected and, therefore, represents the matrix of choice for
the discovery of new accessible biomarkers. In addition, CSF and brain Aβ and Tau correlated with
plasma Aβ and Tau in sporadic AD [83,84]. To this end, measurements in the bloodstream of proteins
and peptide concentrations that originate in the brain are very promising. A decrease in the levels
of Aβ-42, Aβ-40,and the Aβ-42/Aβ-40 ratio was found in the plasma of preclinical AD patients [85].
Other studies focused on Aβ-0 and showed higher levels in samples of AD patients [86]. Blood-based
Tau levels have also been investigated in some studies and found to be elevated in the plasma of
AD patients [87,88]. However, the relatively low levels of Aβ and Tau proteins in peripheral blood
necessitate more sensitive detection techniques to consolidate as diagnostic biomarkers of AD.
Recent studies have revealed that serum neurofilament protein levels correlated with AD [89].
However, this fact was not specific of AD but was also reported in other neurodegenerative diseases [90].
Henceforth, Aβ, Tau, and neurofilaments are not strong enough biomarkers to predict sporadic AD [91],
and it would be useful to account for additional molecules for a more accurate early diagnosis. It has
been found that changes in the plasma concentration of brain-derived neurotrophic factor (BDNF)
depend on the severity of AD [92]. Also, plasma clusterin levels are significantly increased in both,
MCI and AD patients [93], and have been related to increased risk of progression from MCI to AD,
but a slower cognitive decline in AD patients [94].
Extracellular RNA (exRNA) from human biofluids has been recently characterized. In neurological
disorders, brain-derived exRNAs can reach the bloodstream in different ways. One possibility is the
elimination of waste from the brain by the lymphatic system into the bloodstream [95]. A second one is
that blood-brain barrier leakiness described in early AD facilitates the passage of all types of extracellular
molecules [96]. Thus, the presence of exRNAs in the blood allows the study of gene expression in
the central nervous system. In this context, it has been recently described that phosphoglycerate
dehydrogenase (PHGDH) exhibits consistent upregulation in the AD brain transcriptome and is
increased in presymptomatic AD plasma as compared to controls, suggesting the potential utility of
plasma PHGDH exRNA as a presymptomatic indicator of AD [97].
Like in CSF, miRNAs are also considered to be one of the potential candidates for blood-based
biomarkers. It has been reported that several miRNAs downregulate AD-related proteins, including
BACE-1 and APP [98]. Four miRNAs (miR-31, miR-93, miR-143, and miR-146a) were significantly
decreased in AD patients’ serum, suggesting that these could be used as potential diagnostic and
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prognostic markers for dementia. Notably, miR-31, miR-146a, and miR-93 were related to inflammation,
cell apoptosis, and fibrosis. Furthermore, miR-93 and miR-146a were significantly elevated in MCI
compared to controls and miR-31, miR-93, and miR-146a can be used to discriminate AD from other
types of dementia [99]. In addition, the level of miR-206, involved in cognitive decline and memory
deficits, was increased in AD plasma, so it could also be a good AD biomarker candidate [100].
Circulating exRNAs are usually protected by exosomes and other extracellular carriers [101].
Extracellular vesicles (EVs), including exosomes, are small (50–150 nm) membrane microvesicles
involved in cell-to-cell communication, which can go across a healthy blood-brain barrier. EVs contain
not only exRNAs but also other biologically active cargo of molecules specific of their tissue of origin,
such as metabolites and proteins, making EVs a good blood-based biomarker candidate, prognostic
indicator, and therapeutic tool in AD. Isolation of brain-secreted EVs (BEVs) from the blood provides a
minimally invasive way to sample components of brain tissue. Cerebrovascular-derived BEV studies
are sparse in human AD patients, so more research would be needed in this field. Nonetheless, it has
been reported that pathophysiological alterations in AD are, in fact, reflected in the number and
composition of BEVs from neurons, neural precursor cells, and astrocytes [102,103].
As mentioned above, blood is a more complex matrix than CSF, and the high number of cells and
soluble molecules contained in it can lead to interferences. Moreover, the low number of brain-derived
biomarkers in blood requires highly sensitive techniques for their detection. Great variability in the
results depending on the methodology used has been reported, and the fact that several studies show
conflicting results represents a limitation for the use of blood biomarkers as an AD diagnostic tool [104].
For all these reasons, the use of blood biomarkers has not yet been validated [81], and the research of
alternative fluids as urine, tears, and saliva, is challenging (Figure 2).
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Several studies reported significantly elevated Aβ-42 levels in plasma-isolated neuron-derived 
BEVs in AD dementia relative to cognitively normal individuals. EVs may mediate the transcellular 
Figure 2. Schematic overview of noninvasive biomarkers: eyes, saliva, urine and blood. Besides fluid
biomarkers (tears) that can be collected from the eyes, the promising advances in in vivo retinal
imaging could provide an AD diagnosis tool in the near future. Blood-isolated brain secreted
extracellular vesicles (BEVs) derive from three possible brain cell types: neural precursors, neurons
and astrocytes. The content of this blood-isolated BEVs, mainly miRNAs, have been investigated as
potential AD biomarker.
3.1.1. Neuron-Derived BEVs in Blood
Several studies reported significantly elevated Aβ-42 levels in plasma-isolated neuron-derived
BEVs in AD dementia relative to cognitively normal individuals. EVs may mediate the transcellular
spread of Aβ peptide by destabilizing calcium cell homeostasis and damaging mitochondrial function;
thus making neurons more vulnerable to excitotoxicity [105]. Plasma Aβ-42 has the potential to be
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used both, as a novel earlier biomarkers of AD, as well as a marker of AD progression, having the same
capacity as Aβ-42 in CSF for the diagnosis of AD [83]. Nonetheless, the EV concentration is higher in
blood plasma than in CSF [105], making this a more sensitive biomarker.
Regarding Tau levels in the plasma, the association of neuron-derived BEVs with AD has yet
to reach a consensus. Although three studies [83,106,107] found elevated phospho-Tau levels in AD
dementia, these reached a plateau as early as 10 years before AD diagnosis, making it a worse marker
of AD progression than Aβ-42 [107]. In addition, three other studies [108–110] showed no statistical
difference in Tau fragments.
Protein cargo form plasma and serum isolated neuron-derived BEVs included synaptic proteins like
neurogranin, synaptotagmin, synaptopodin, and synaptophysin, which was reduced in individuals with
AD dementia [111]. However, the potential of being selective biomarkers of AD appears low because
these synaptic proteins were also reduced in MCI and Parkinson’s disease. Decreased levels of the
growth-associated protein 43 (GAP43), synaptosomal-associated protein-25 (SNAP-25), and synapsin 1
were also observed in blood-isolated neuron-derived BEVs of AD patients [103]. Therefore, synaptic
proteins cargo of neuron-derived BEVs demonstrates some biomarker potential in AD, although more
studies are needed to confirm this.
Insulin pathway proteins are deregulated in AD as well. Specifically, higher phospho-Ser312-insulin
receptor substrate-1 (IRS-1) and lower phospho-panTyr-IRS-1 levels were reported in blood isolated
neuron-derived BEVS of AD patients [112,113]. So IRS-1 level, as well as being used to monitor insulin
administration [114], could also be used as an AD biomarker.
Lysosomal proteins of neuron-derived BEVs from plasma were also found to discriminate
AD dementia. Levels of cathepsin D, alysosome-associated membrane protein, and ubiquitinated
proteins were significantly increased in AD patients, and levels of heat-shock protein-70 were
diminished in preclinical and clinical AD, suggesting that neuronal lysosomal dysfunction is an
early phenomenon in AD [115].
Finally, research from Winston et al. [106] demonstrated that the level of the repressor element
1-silencing transcription factor (REST) was significantly lower in AD patients and MCI compared to
control subjects.
3.1.2. Neural Precursor Cell-Derived BEVs in Blood
Chondroitin sulfate proteoglycan (CSPG4) cells are a subtype of neuronal precursor cells that
release neurotrophic factors implicated in neuronal growth and survival. Four assessed neurotrophic
factors (hepatocyte growth factor, fibroblast growth factors 2 and 13, and type 1 insulin-like growth
factor) were significantly lower in CSPG4 neuronal precursor cells-derived BEVs from preclinical AD
patients, being able to use these neurotrophic factors as early biomarkers of AD. No significant further
decrease was found during the course of the disease [116], though.
3.1.3. Astrocyte-Derived BEVs in Blood
Astrocyte-derived BEVs have also been reported to cargo Tau, Aβ-42, and APP pathway proteins.
However, only levels of BACE1, sAPPβ, complement proteins, and glial-derived neurotrophic factor
(GDNF) were significantly deregulated in AD. The levels of BACE1, sAPPβ, and complement
proteins were higher [117], and the levels of GDNF were lower in AD patients compared to control
individuals [118].
3.1.4. MicroRNA Cargo of Blood-Isolated EVs
The levels of miRNAs in peripheral blood can be affected by multiple factors and may also vary
among different sample types. In this regard, exosomal miRNAs effectively avoid that problem because
of their stable expression. Exosomes are a subtype of EV with a size of 40–100 nm that are released from
most types of cells, including neurons [106]. Recent studies have shown that exosomes, in addition
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to functional proteins, carry mRNA and miRNAs [119], and abnormal expression of these exosomal
miRNAs has been detected in AD [120].
More than 40 differentially expressed plasma- and serum-isolated EV-associated miRNAs have
been described in AD and MCI relative to control individuals [121–127]. For example, exosomal
miR-342-3p [123], miR-125a-5p, miR-125b-5p, and miR-451a, associated with fatty acid biosynthesis,
hippo signaling, and protein processing in the endoplasmic reticulum were significantly lower in AD
patients, and their level correlated with the extent of cognitive impairment [128]. Decreased levels of
exosomal miRNA 23a-3p, ex-let-7i-5p, ex-miR-126-3p, and ex-miR-151a-3p, which target genes involved
in cell death, among others, suggest that changes in the plasma level of AD individuals exhibit diagnostic
value [129]. The exosomal miR-223, which regulates inflammation by interacting with different targets,
was also significantly decreased in AD patients [125]. On the other hand, Barbagallo et al. found
that exosomal miR-29a was significantly increased in AD patients [130] and Cheng et al. reported
14 significantly upregulated exosomal miRNAs [122]. It is also important to mention three of those
exosomal miRNAs that have been reported in at least two different studies—the decrease of miR-193b
and miR-342-3p [121,124], and both, the increase and decrease of miR3065-5p [122,123]. miR-193b is
known to repress the expression of APP and PSEN1 mRNAs, so its reduction may promote amyloidosis,
and miR 342-3p is suggested to affect Tau phosphorylation and aggregation.
These studies suggest that specific blood exosome miRNAs can be used as diagnostic biomarkers
of AD and, additionally, are able to reflect the disease progression. It has also been reported that the
combination of miR-135a, miR-193b, and miR-384, modulators of APP or BACE1 expression, are good
for early AD diagnosis [124], demonstrating that a combined biomarker signature is better than a
particular one for diagnosis. These studies have been carried out in already clinically diagnosed
AD patients, so further studies will be necessary to evaluate the potential of these miRNAs as early
biomarkers of AD. Table 2 summarizes all the information regarding AD-related miRNAs found in
blood, as well as in CSF.
Table 2. AD-related main miRNA.
miRNAs Regulation and Localization References
miR-let-7d-5p, miR-let-7g-5p, miR-26b-5p, miR-191-5p ↓ Blood [131]
miR-125a-5p ↓ Blood [128]
miR-126-3p, miR-23a-3p, miR-151a-3p ↓ Blood [129]
miR-135b ↓ Blood [132]
miR-181a ↓ Blood [133]
miR-194-5p ↓ Blood [134]
miR-19b-3p, miR-29c-3p, miR-125b-3p ↓ Blood [135]
miR-31, miR-93 ↓ Blood [99]
miR-3613-3p, miR-3916, miR-4772-3p, miR-185-5p, miR-20b-3p ↓ Blood [123]
miR-501-3p ↓ Blood [136]
miR-545-3p ↓ Blood [137]
miR-181c ↓ Blood, ↓ Brain [133,138]
miR-139-5p, miR-141-3p, miR-150-5p, miR-152-3p, miR-23b-3p,
miR-24-3p, miR-338-3p, miR-342-3p, miR-125b-5p, miR-342-5p ↓ Blood, ↓ CSF [123]
miR-1306-5p ↓ Blood, ↓ CSF [122,139]
miR-143 ↓ Blood, ↓ CSF [99,133]
miR-15b ↓ Blood, ↓ CSF [131,133]
miR-15b-3p ↓ Blood, ↓ CSF [122,139]
miR-193b ↓ Blood, ↓ CSF [121,124]
miR-223 ↓ Blood, ↓ CSF [125,140]
miR-451a ↓ Blood, ↓ CSF [128,139]
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miRNAs Regulation and Localization References
miR-106, miR-107, miR-181 ↓ Brain [69]
miR-106b ↓ Brain [138]
miR-137, miR-139, miR-153, miR-183, miR-135, miR-124b ↓ Brain [66]
miR-15a, miR-19b, miR-26b, miR-330 ↓ Brain [138]
miR-425 ↓ Brain [133]
miR-146b ↓ Brain, ↓ CSF [133]
miR-210 ↓ Brain, ↓ CSF [133,141]
miR-10, miR-126, miR-127, miR-154, miR-194, miR-195, miR-199a,
miR-214, miR-221, miR-338, miR-422b, miR-451, miR-455, miR-497,
miR-99a, miR-27a-3p
↓ CSF [133]
miR-16-2, miR-16-5p, miR-605-5p, mir-9-5p, miR-598, miR-136-3p ↓ CSF [139]
miR-200b ↓ CSF [142]
miR-214-3p, miR-299-5p ↓ CSF [132,143]
miR-29b-3p ↓ CSF [123]
miR-29c ↓ CSF [134]
miR-29 ↓ Blood, ↓ Brain, ↑Brain [69,131,133]
miR-125b ↓ Blood, ↑ Brain, ↑ CSF [65,66,123]
miR-146a ↓ Blood, ↑ Brain, ↑ CSF [69,71,99]
miR-26a ↓ Brain (frontal cortex), ↑ Brain(hippocampus) [133]
miR-3065-5p ↓ Blood, ↑ Brain [122,123]
let-7i-5p ↓ Blood, ↑ CSF [129,134]
miR-106a-5p, miR-20-5p, miR-425-5p, miR-18b-5p, miR-582-5p ↑ Blood [122]
miR-106b-3p, miR-20b-5p, miR-146a-5p, miR-195-5p, niR-497-5p ↑ Blood [135]
miR-455-3p, miR-4668-5p ↑ Blood [144]
miR-5001-3p ↑ Blood [123]
miR-519 ↑ Blood [140]
miR-548at-5p ↑ Blood [123]
miR-590-5p ↑ Blood [134]
miR-101-3p, miR-106b-5p, miR-143-3p, miR-335-5p, miR-361-5p, ↑ Blood, ↑ CSF [122]
miR-138-5p ↑ Blood, ↑ CSF [123]
miR-155 ↑ Blood, ↑ CSF [71,131]
miR-15a-5p ↑ Blood, ↑ CSF [122,134]
miR-659-5p ↑ Blood, ↑ CSF [123]
miR-100, miR-145, miR-148a, miR-27, miR-34a, miR-381, miR-422a,
miR-423, miR-92 ↑ Brain [133]
miR-128 ↑ Brain [66]
miR-34 ↑ Brain [69]
miR-98 ↑ Brain [138]
miR-let-7b, miR-let7e ↑ CSF [145]
miR-let-7f, miR-105, miR-138, miR-141, miR-151, miR-186, miR-191,
miR-197, miR-204, miR-205, miR-216, miR-302b, miR-30a-3p,
miR-30a-5p, miR-30b, miR-30d, miR-32, miR-345, miR-362, miR-371,
miR-374, miR-375, miR-380-3p, miR-429, miR-448, miR-449,
miR-494, miR-501, miR-517, miR-518, miR-520, miR-526
↑ CSF [133]
miR-20a-5p ↑ CSF [122]
miR-222 ↑ CSF [146]
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miR-331-5p, miR-485-5p, miR-132-5p ↑ CSF [139]
miR-613 ↑ CSF [147]
miR-200b-5p ↑ Eyes [148]
miR-93-5p ↑ ↓ Blood, ↑ CSF [122,135]
miR-101 ↑ Blood, ↓ Brain [131,138]
miR-132, miR-212 ↑ Blood, ↓ Brain [126,133]
miR-200c ↑ Blood, ↓ Brain (frontal cortex), ↑ Brain(hippocampus) [133,149]
miR-9 ↑ Blood, ↓ Brain (frontal cortex, cortex), ↑ Brain(hippocampus), ↑ CSF [66,71,131,133,138]
miR-30e-5p ↑ Blood, ↑ Brain, ↑ CSF, [122,133]
miR-29a ↑ Blood, ↓ Brain, ↑ CSF [73,74,130]
miR-206 ↑ Blood, ↑ CSF, ↑ Eyes [100,150]
miR-142-5p ↑ Blood, ↓ CSF [133,134]
miR-384 ↑ Blood, ↓ CSF [124]
miR-135a ↑ Blood, ↓ CSF, ↑ CSF [124,133,142]
miR-125a ↓ Brain, ↑ CSF [66,133]
miR-29b ↓ Blood, ↓ Brain, ↑ CSF [73,74,131]
miR-30c ↑ Brain (frontal cortex), ↓ Brain (hippocampus), ↑ CSF [133]
3.2. Ocular Biomarkers
AD not only causes neurodegenerative changes in the brain but also produces structural and
functional alterations in the retinal neural and non-neural ocular tissues [151]. Engagingly, specific
biomarkers of AD have been reported as well in retinal degeneration and visual function impairment [152],
sharing pathophysiological features with glaucoma and age-related macular degeneration (AMD) [153].
The similarity between ocular and cerebral tissues suggests that these ocular manifestations may be used
as early biomarkers of AD.
Numerous studies have identified Aβdepositions in the lens and retina. Aβ-accumulates in the retina
in an age-dependent manner in a mouse model of AD and correlates with amyloid plaques in the brain.
Interestingly, the appearance of retinal amyloid plaques precedes that in the brain [154]. Elevated levels of
Aβ1-42 and amyloid plaques were also reported in the retinas of confirmed AD patients [152]. This retinal
Aβ can be detected noninvasively by using hyperspectral imaging microscopy or with modified endoscope
applied to the corneal surface [155].
In the same way, Aβ has been identified in the lens of rodents, monkeys, and humans in several
studies. The accumulation of the isoforms Aβ1-40 and Aβ1-42 has been demonstrated in the lenses of
AD people post mortem at concentrations comparable with those in the brain [156]. In the same way,
a clinical trial carried out on AD patients, and age-matched healthy volunteers confirmed the presence
of Aβ in the lens of the first and its correlation in the brain using imaging techniques [157].
Moreover, changes such as thinning of the nerve cell layer, optic nerve atrophy, and the loss
of retinal ganglion cells [156,158] were reported in AD, resulting in visual functional impairment
and circadian disturbances [159]. Specifically, a study of melanopsin retinal ganglion cells (mRGCs),
a photosensitive subtype of ganglion cells in charge of the circadian rhythms, has shown a significant
decrease of this neuronal cell type in people with AD but not in healthy controls, with a prominent Aβ
accumulation around mRGCs [160,161].
Other ocular tissues, such as the cornea, which is the outermost layer of the eye and, therefore,
grants accessibility, could be used as potential biomarker for the diagnosis of AD. Dutescu et al. [162]
found the cytoplasmic expression of APP in the epithelial cell layer of the cornea of transgenic
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mouse models of AD. More recently, Choi et al. corroborated the expression of APP, together with
proteins involved in its processing such as BACE1, in human corneal fibroblasts, and the corneal
epithelium [163].
For the development of a novel noninvasive screening and diagnostic tool, the ocular examination
sector appears promising. In this context, tear fluid provides a viable source widely used for biomarker
studies [164], including neurodegenerative diseases [165]. Tear samples are easy to collect and contain
a lot of proteins, most notably lipocalin-1, lactotransferrin, and lysozyme C, involved in immune and
inflammatory processes [166].
Against this backdrop, total protein concentration and composition modifications in tears and an
abnormal flow rate and tear function have been described in AD patients [167], supporting the use of
tears as a new noninvasive method to discriminate AD patients. Specifically, lipocalin-1, dermcidin,
lysozyme C, and lacritin were shown to be potential biomarkers, with an 81% sensitivity and 77%
specificity [168]. In addition, the elongation initiation factor 4E (eIF4E) was exclusively expressed in
tear samples from AD patients. Total miRNA content was also higher in tears from AD individuals
and miR-200b-5p was significantly elevated in AD tear fluid samples compared to controls [148].
Tears could be useful for first screening, and patients with a positive tear analysis test might be further
evaluated to establish an early diagnosis. Assessments of pupillary responses and retinal vasculature
have also been considered as biomarkers of AD, but are not yet conclusively validated for clinical
diagnosis. Further research is needed in order to use ocular biomarkers as AD early diagnostic tools.
Regarding the use of ocular biomarkers, as well as other novel matrices, some limitations arise,
like the amall volume of the samples or the standardization of the collection procedures.
3.3. Salivary Biomarkers
Due to the link between the decline of the salivary glands and AD [169,170], it seems likely that
AD-specific proteins are expressed in the salivary glands. Salivary epithelial cells express APP and Aβ,
and changes in the CSF may be reflected in the saliva [171,172]. Saliva is a novel matrix; therefore,
there are still some conflicts between studies. One study has revealed no changes in Aβ-40 protein
between AD patients and age-matched controls and high levels of Aβ-42 only in MCI patients (in
severe AD stages, these levels returned to control values) [173]. A second study has shown that
salivary levels of Aβ-40 and Aβ-42 peptides increase as the severity of AD grows, even as far as a
three-fold increase in the case of Aβ-42 levels [174,175]. Moreover, studies where the genetic condition
was considered, suggested that salivary Aβ-42 levels were associated with familial AD more than
with sporadic AD [173,176]. Among the reasons for these different results may be the distinct Aβ
peptide detection and saliva collection techniques, as well as the different disease stages of the patients.
There is a clear need for more studies and larger sample size to conclude whether there is a relationship
between salivary Aβ-42 and Aβ-40 levels and AD progression.
Another typical candidate protein for analysis in the saliva is Tau, which is expressed and secreted
by the acinar epithelial cells of the salivary glands [177]. No changes have been seen in total Tau levels
between healthy elderly, MCI, and AD patients [178]. In contrast, the phospho-Tau/total-Tau ratio looks
promising in this regard. A high phospho-Tau/total-Tau ratio was found in AD patients compared
with non-amnestic people [179]. Though no conclusive results were found that pointed in a particular
direction, the few results available suggest that studies should be directed at investigating different
sites of Tau protein phosphorylation as possible candidates for biomarkers of the pathology [180].
Interestingly, the study of one of the most important antimicrobial peptides in saliva, lactoferrin,
seems to have a high accuracy in AD diagnosis. Lactoferrin participates in modulating the immune
response and inflammation process due to its high defense action. It has been seen that low
lactoferrin levels in saliva of healthy people mean a clear risk factor to develop amnestic MCI and AD
dementia [181].
Another proposed candidate in the saliva is the acetylcholinesterase enzyme (AChE), which plays
a role in removing the accumulation of acetylcholine (ACh) in Aβ-plaques and NFTs. Although there
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are still few studies, no evidence has been found to suggest that AChE activity is different between AD
patients and control individuals of the same cognitive age not taking anticholinergics [182,183].
All these results support the need for longitudinal studies with a larger number of subjects to
find conclusive results regarding the potential use of the expression of certain molecules in saliva as
biomarkers in AD.
3.4. Urine Biomarkers
Oxidative stress plays an important role in AD, and the study of guide molecules of oxidative
brain damage might be promising early hallmarks of AD in urine. Some metabolites such as the
isoprostane 8,12-iso-iPF(2alpha)-VI, a free amino acid generated by lipid peroxidation whose levels in
urine were higher at advanced AD stages, might predict the progression of the pathology from MCI to
AD dementia [184,185].
Other metabolite candidates that reflect oxidative DNA damage can be oxidized nucleosides
such as pseudouridine, 1-methyladenosine, 3-methyluridine, N2, N2-dimethylguanosine,
8-hydroxy-2′-deoxyguanosine, and 2-deoxyguanosine, whose levels were higher in AD patients
than in healthy elderly [186].
Other promising markers are some proteins found in urine. Given that the AD-associated neuronal
thread protein (AD7c-NTP) was isolated from brain tissue and was increased in the CSF of AD people,
correlating with the severity of dementia [187], it has been suggested as a potential biomarker of AD.
Recently, a high specificity of this protein has been demonstrated to predict Aβ-plaques in MCI patients
when present in the urine [188]. These findings are supported by a meta-analysis proposing the use of
urinary AD7c-NTP for the early diagnosis of probable AD [189]. In a longitudinal study carried out in
2018, high levels of albumin, a protein characteristic of chronic kidney disease, were detected in AD
patients in comparison with age-matched healthy individuals [190]. According to Yao et al. [191], and in
the same direction, the urine of patients with AD showed significantly decreased levels of osteopontin
and increased levels of gelsolin and insulin-like growth factor-binding protein 7 in comparison with
healthy elderly. All of them are proteins involved in several pathological processes of AD [192–194],
and they may serve as potential novel urinary biomarkers.
Although it is evident the need for longitudinal studies with bigger samples to get conclusive
results verifying the diagnostic value of these peripheral markers, the scientific community is hopeful
that the biomarkers in these noninvasive new matrices will be able to demonstrate diagnostic value.
4. Concluding Remarks and Future Perspectives
In addition to the established Aβ-42, total-Tau, phospho-Tau, and CSF biomarkers, several
candidate more accessible fluid biomarkers have shown potential for clinical use in AD to support
diagnosis and prognosis.
Blood has been the most widely studied fluid biomarker, being neuron-derived BEVs the most
investigated biomarker among blood-isolated EVs. The majority of the studies reported elevated
Aβ-42 levels in blood-isolated neuron derived BEVs in AD and MCI patients early in the course
of the disease, and also with disease progression. With regard to synaptic proteins assessed in
neuron-derived BEVs, growth-associated protein 43 (GAP43) also showed some potential as a marker
of AD progression. Henceforth, BEVs have emerged as a novel potential blood-based biomarker
of AD. It would also be interesting to study BEVs from other components of the brain, such as the
cerebrovasculature, that are affected in the early stages of AD and that would allow us to obtain more
sensitive blood-based biomarkers.
Tear fluid also provides a viable source widely used for biomarker studies and lipocalin-1,
dermcidin, lysozyme C, lacritin, eIF4E, and the microRNA-200b-5p were shown to be potential
biomarkers. The relationship between salivary Aβ-42, Aβ-40, and lactoferrin levels and the progression
of AD point out to also be biomarker candidates of AD and MCI in saliva. Lastly, several metabolites
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and proteins like AD7c-NTP, osteopontin, gelsolin, or insulin-like growth factor-binding protein 7 in
urine are involved in several pathological processes in AD.
Inflammatory and oxidative stress markers are very common hallmarks of neurodegenerative
diseases such as amyotrophic lateral sclerosis, Parkinson, Huntington, and AD. It has been suggested
that these alterations reflect inflammatory mechanisms within the central nervous system that parallel
the neurodegenerative process [56]. In this review, we have mentioned several neuroinflammation
candidate biomarkers such as TREM2, MCP-1, and YKL-40, which have been extensively investigated in
AD patients. Particularly, there is strong evidence regarding CSF YKL-40 levels, not only as a potential
biomarker for AD diagnosis, but also as a predictor of disease progression from the asymptomatic stage
to prodromal, and eventually dementia stages [51]. However, the idea that these inflammation-related
proteins could differentiate AD from other dementias is controversial since neurodegeneration and
neuroinflammation go hand in hand and inflammation on its own cannot be considered a marker of a
specific pathology. There is a clear lack of reliable inflammatory biomarkers that can be used in the
context of accurate diagnosis.
Despite recent studies strongly indicating the potential of fluid biomarkers as early diagnosis of
AD, these biomarkers are not yet validated for clinical use and further research is needed before these
can be regulatory qualified and applied clinically. Future work should establish normative ranges for
the levels of these biomarkers to indicate a pathology that may find clinical applications. If we provided
early diagnosis and treatment before the underlying pathology manifests clinically, AD patients’ quality
of life could notably improve and could be an approach to prevent its irreversible consequences.
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